Skip to main
STE

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Steris is a leader in contract sterilization, healthcare equipment, and life sciences services with a strong start to FY27 driven by 6% organic growth and increased equipment orders, backlog, and HC service sales. With a $600M investment in a North Carolina facility and a new share buyback program, Steris is well positioned to drive sustainable margin expansion and a targeted 10% ROIC while managing macro volatility. However, potential risks include sensitivity to procedure volumes, supply chain and inflationary pressures, and lumpiness of capital equipment buying.

Bears say

Steris is expected to experience modest growth in all segments, but the negative impact of divesting its dental products business has not yet been fully reflected in its financials. Additionally, the company's recent inversion to Ireland raises concerns about potential tax implications and legal complications. Furthermore, the slight increase in capex and decrease in FCF guidance indicate potential financial strain in the coming year.

STERIS (STE) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 3 analysts, STERIS (STE) has a Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $271.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $271.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.